Dr. Mohammed Salhab
Claim this profileParker Adventist Hospital
Studies Breast Cancer
Studies Non-Small Cell Lung Cancer
3 reported clinical trials
10 drugs studied
Area of expertise
1Breast Cancer
Stage IV
Stage II
Stage III
2Non-Small Cell Lung Cancer
Stage II
Stage III
EGFR negative
Affiliated Hospitals
Clinical Trials Mohammed Salhab is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Eribulin + Chemotherapy
for Bladder Cancer
This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.
Recruiting2 awards Phase 3
More about Mohammed Salhab
Clinical Trial Related2 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Mohammed Salhab has experience with
- Gemcitabine Hydrochloride
- Paclitaxel
- Carboplatin
- Pembrolizumab
- Pemetrexed Disodium
- Docetaxel
Breakdown of trials Mohammed Salhab has run
Breast Cancer
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Lung Cancer
Bladder Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Mohammed Salhab specialize in?
Is Mohammed Salhab currently recruiting for clinical trials?
Are there any treatments that Mohammed Salhab has studied deeply?
What is the best way to schedule an appointment with Mohammed Salhab?
What is the office address of Mohammed Salhab?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.